PODCAST: Put yourself in your customers’ shoes; Avik Pal uses technology to change the game with clinical trials

Subscribe to hear more: Apple Podcast Google Podcast Spotify

In this episode of The Slalom Daily Dose Podcast, we speak with Avik Pal, Founder and CEO at CliniOps. Avik shares the story of his journey from technology maven to social entrepreneur to clinical trials disruptor. Through his alumni work with the Indian Institute of Technology, he continues to create opportunities for education and innovation in the Bay Area.

Avik has extensive experience in enterprise applications, managing global delivery at various fortune 500 clients across North America, Europe, Latin America & Asia. Before starting CliniOps, he worked with NTT DATA. Prior to that, he worked with two successful start-ups, managing global delivery at FocusFrame (acquired by Hexaware Technologies) and Euclid (acquired by Persistent Systems).

He is a Founding Board member at iKure, a social entrepreneurship healthcare startup in India, focussing on affordable healthcare for the last mile. He was also the President of ‘IIT Foundation’, San Francisco Bay Area Chapter, the alumni association of Indian Institute of Technology, Kharagpur, for 4 years.

Avik holds a B. Tech (Honors) from IIT Kharagpur, and an MBA from University of San Francisco, where he was awarded the ‘McLaren Fellowship’.

And, here are links to topics discussed on this episode:


Slalom partners with healthcare, biotech and pharmaceutical leaders to strengthen their organizations, improve their systems, and help with some of their most strategic business challenges. Find out more about our people, our company and what we do.

Slalom Daily Dose

Healthcare and life sciences perspectives from industry experts at Slalom.

Slalom Healthcare & Life Sciences

Written by

We are Slalom's diverse group of healthcare and life sciences consultants, who bring industry expertise and a passion for driving change to this publication.

Slalom Daily Dose

Healthcare and life sciences perspectives from industry experts at Slalom.